MA51312A - METHODS AND COMPOSITIONS FOR INDUCING AN IMMUNE RESPONSE AGAINST THE HEPATITIS B VIRUS (HBV) - Google Patents

METHODS AND COMPOSITIONS FOR INDUCING AN IMMUNE RESPONSE AGAINST THE HEPATITIS B VIRUS (HBV)

Info

Publication number
MA51312A
MA51312A MA051312A MA51312A MA51312A MA 51312 A MA51312 A MA 51312A MA 051312 A MA051312 A MA 051312A MA 51312 A MA51312 A MA 51312A MA 51312 A MA51312 A MA 51312A
Authority
MA
Morocco
Prior art keywords
hbv
hepatitis
virus
inducing
compositions
Prior art date
Application number
MA051312A
Other languages
French (fr)
Inventor
Daniel Boden
Jerome Hubertina Henricus Victor Custers
Pooter Dorien De
Helen Horton
Markus Kalla
Jean-Marc Edmond Fernand Marie Neefs
Soumitra Roy
Roland Christian Zahn
Original Assignee
Bavarian Nordic As
Janssen Sciences Ireland Unlimited Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bavarian Nordic As, Janssen Sciences Ireland Unlimited Co filed Critical Bavarian Nordic As
Publication of MA51312A publication Critical patent/MA51312A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/02—Hepadnaviridae, e.g. hepatitis B virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10131—Uses of virus other than therapeutic or vaccine, e.g. disinfectant
MA051312A 2017-12-19 2018-12-18 METHODS AND COMPOSITIONS FOR INDUCING AN IMMUNE RESPONSE AGAINST THE HEPATITIS B VIRUS (HBV) MA51312A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762607439P 2017-12-19 2017-12-19
IB2017058148 2017-12-19

Publications (1)

Publication Number Publication Date
MA51312A true MA51312A (en) 2020-10-28

Family

ID=65201641

Family Applications (1)

Application Number Title Priority Date Filing Date
MA051312A MA51312A (en) 2017-12-19 2018-12-18 METHODS AND COMPOSITIONS FOR INDUCING AN IMMUNE RESPONSE AGAINST THE HEPATITIS B VIRUS (HBV)

Country Status (12)

Country Link
EP (1) EP3727446A1 (en)
JP (1) JP2021506300A (en)
KR (1) KR20200100745A (en)
CN (1) CN111741766A (en)
AU (1) AU2018389786A1 (en)
BR (1) BR112020012273A2 (en)
CA (1) CA3086325A1 (en)
IL (1) IL275423A (en)
MA (1) MA51312A (en)
MX (1) MX2020006471A (en)
SG (1) SG11202005710YA (en)
WO (1) WO2019123250A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA202091516A1 (en) 2017-12-19 2020-11-03 Янссен Сайенсиз Айрлэнд Анлимитед Компани METHODS AND COMPOSITIONS FOR INDUCING IMMUNE RESPONSE AGAINST HEPATITIS B VIRUS (HBV)
EA202091517A1 (en) 2017-12-19 2020-11-03 Янссен Сайенсиз Айрлэнд Анлимитед Компани METHODS AND DEVICE FOR DELIVERY OF VACCINES AGAINST HEPATITIS B VIRUS (HBV)
US11021692B2 (en) 2017-12-19 2021-06-01 Janssen Sciences Ireland Unlimited Company Hepatitis B virus (HBV) vaccines and uses thereof
US20220313815A1 (en) * 2019-06-20 2022-10-06 Janssen Sciences Ireland Unlimited Company Self-replicating rna molecules for hepatitis b virus (hbv) vaccines and uses thereof

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA92121A (en) 1904-11-07 1905-03-14 William Waid Paddock Pressure filter
US5273525A (en) 1992-08-13 1993-12-28 Btx Inc. Injection and electroporation apparatus for drug and gene delivery
US6041252A (en) 1995-06-07 2000-03-21 Ichor Medical Systems Inc. Drug delivery system and method
US6083716A (en) 1996-09-06 2000-07-04 The Trustees Of The University Of Pennsylvania Chimpanzee adenovirus vectors
US6261281B1 (en) 1997-04-03 2001-07-17 Electrofect As Method for genetic immunization and introduction of molecules into skeletal muscle and immune cells
EA002087B1 (en) 1997-04-03 2001-12-24 Электрофект Ас Method for introducing pharmaceutical drugs and nucleic acids into skeletal muscle
US5873849A (en) 1997-04-24 1999-02-23 Ichor Medical Systems, Inc. Electrodes and electrode arrays for generating electroporation inducing electrical fields
GB0023203D0 (en) 2000-09-21 2000-11-01 Isis Innovation Vaccination method
US6117660A (en) 1997-06-10 2000-09-12 Cytopulse Sciences, Inc. Method and apparatus for treating materials with electrical fields having varying orientations
CZ299473B6 (en) 1997-06-30 2008-08-06 Rhone-Poulenc Rorer S. A. Nucleic acid and electric field as associated product for transfer of nucleic acid into cells of adversely stripped musculature
US6697669B2 (en) 1998-07-13 2004-02-24 Genetronics, Inc. Skin and muscle-targeted gene therapy by pulsed electrical field
US6319901B1 (en) 1998-10-15 2001-11-20 Ichor Medical Systems, Inc. Methods for prolonging cell membrane permeability
ATE519854T1 (en) 1999-05-17 2011-08-15 Crucell Holland Bv RECOMBINANT ADENOVIRUS BASED ON SEROTYPE 48 (AD48).
US6913922B1 (en) 1999-05-18 2005-07-05 Crucell Holland B.V. Serotype of adenovirus and uses thereof
NZ524661A (en) 2000-11-23 2005-03-24 Bavarian Nordic As Modified vaccinia ankara virus variant
CA2466413C (en) 2001-12-04 2014-11-04 Bavarian Nordic A/S Flavivirus ns1 subunit vaccine
US8209006B2 (en) 2002-03-07 2012-06-26 Vgx Pharmaceuticals, Inc. Constant current electroporation device and methods of use
US7245963B2 (en) 2002-03-07 2007-07-17 Advisys, Inc. Electrode assembly for constant-current electroporation and use
US6912417B1 (en) 2002-04-05 2005-06-28 Ichor Medical Systmes, Inc. Method and apparatus for delivery of therapeutic agents
CA2477954C (en) 2002-04-25 2012-07-10 Crucell Holland B.V. Means and methods for the production of adenovirus vectors
CA2478508C (en) 2002-04-25 2013-07-02 Crucell Holland B.V. Stable adenoviral vectors and methods for propagation thereof
US7328064B2 (en) 2002-07-04 2008-02-05 Inovio As Electroporation device and injection apparatus
CA2553541C (en) 2004-01-23 2015-04-21 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Chimpanzee adenovirus vaccine carriers
ES2695235T3 (en) 2004-03-08 2019-01-02 Ichor Medical Systems Inc Improved apparatus for the delivery, electrically mediated, of therapeutic agents
CN101248173A (en) * 2005-04-08 2008-08-20 墨尔本保健公司 Variants of hepatitis b virus with resistance to anti-viral nucleoside agents and applications thereof
WO2007104792A2 (en) 2006-03-16 2007-09-20 Crucell Holland B.V. Recombinant adenoviruses based on serotype 26 and 48, and use thereof
SG175627A1 (en) 2006-10-17 2011-11-28 Vgx Pharmaceuticals Inc Electroporation devices and methods of using same forelectroporation of cells in mammals
EP2222336A2 (en) * 2007-10-29 2010-09-01 GENimmune N.V. Methods and kits for inducing a ctl response using a prime boost regimen
JP2012509678A (en) 2008-11-27 2012-04-26 バヴァリアン・ノルディック・アクティーゼルスカブ Promoter for recombinant virus expression
WO2010085984A1 (en) 2009-02-02 2010-08-05 Okairos Ag Simian adenovirus nucleic acid- and amino acid-sequences, vectors containing same, and uses thereof
JP5882741B2 (en) 2009-02-02 2016-03-09 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム Nucleic acid and amino acid sequences of simian adenovirus, vectors containing the same, and uses thereof
US8394385B2 (en) 2009-03-13 2013-03-12 Bavarian Nordic A/S Optimized early-late promoter combined with repeated vaccination favors cytotoxic T cell response against recombinant antigen in MVA vaccines
KR20120052352A (en) * 2009-08-07 2012-05-23 트랜스진 에스.에이. Composition for treating hbv infection
US9701718B2 (en) 2010-12-14 2017-07-11 Janssen Vaccines & Prevention B.V. Adenovirus serotype 26 and serotype 35 filovirus vaccines
US10111946B2 (en) 2012-06-22 2018-10-30 Bavarian Nordic A/S Poxviral vectors for low antibody response after a first priming immunization
KR20200087880A (en) 2012-10-28 2020-07-21 버베리안 노딕 에이/에스 Pr13.5 PROMOTER FOR ROBUST T-CELL AND ANTIBODY RESPONSES
KR102565284B1 (en) 2015-07-31 2023-08-08 버베리안 노딕 에이/에스 Promoters for enhancing expression in poxviruses
CA3002508A1 (en) * 2016-01-12 2017-07-20 Ulrike Protzer Means and methods for treating hbv
JP6910075B2 (en) 2016-03-28 2021-07-28 イコル メディカル システムズ，インク． Methods and devices for delivery of therapeutic agents

Also Published As

Publication number Publication date
BR112020012273A2 (en) 2020-11-24
KR20200100745A (en) 2020-08-26
AU2018389786A1 (en) 2020-06-18
MX2020006471A (en) 2020-09-22
IL275423A (en) 2020-08-31
CN111741766A (en) 2020-10-02
WO2019123250A1 (en) 2019-06-27
EP3727446A1 (en) 2020-10-28
SG11202005710YA (en) 2020-07-29
JP2021506300A (en) 2021-02-22
CA3086325A1 (en) 2019-06-27

Similar Documents

Publication Publication Date Title
MA50813A (en) EPSTEIN-BARR VIRUS VACCINES
ZA201906252B (en) Hepatitis b virus surface antigen inhibitor
MA51312A (en) METHODS AND COMPOSITIONS FOR INDUCING AN IMMUNE RESPONSE AGAINST THE HEPATITIS B VIRUS (HBV)
IL258697A (en) Crispr/cas-related methods and compositions for treating hepatitis b virus
HK1255502A1 (en) Hepatitis b virus (hbv) irna compositions and methods of use thereof
HK1255847A1 (en) Vaccines against hepatitis b virus
EP3325097A4 (en) Compositions and agents against hepatitis b virus and uses thereof
MA50520A (en) NEW HIGHLY ACTIVE INDOLE-2-CARBOXAMIDES PYRAZOLO-PIPERIDINE SUBSTITUTE AGAINST THE HEPATITIS B VIRUS (HBV)
MA52701A (en) COMBINATION WITH TLR7 AGONIST AND HEPATITIS B VIRUS CAPSIDE ASSEMBLY INHIBITOR
MA51311A (en) HEPATITIS B VIRUS (HBV) VACCINES AND RELATED USES
HK1248278A1 (en) Compositions and methods for silencing hepatitis b virus gene expression
MA50524A (en) NEW HIGHLY ACTIVE AMINO-THIAZOLE-SUBSTITUTED INDOLE-2-CARBOXAMIDES ACTING AGAINST THE HEPATITIS B VIRUS (HBV)
MA51292A (en) METHODS AND APPARATUS FOR GIVING VACCINES AGAINST THE HEPATITIS B VIRUS (HBV)
IL265921A (en) Engineered meganucleases specific for recognition sequences in the hepatitis b virus genome
EP3632914A4 (en) Hepatitis b virus surface antigen inhibitor
IL290924A (en) Hepatitis b virus vaccines
HK1259329A1 (en) Pharmaceutical composition that includes the surface and nucleocapsid antigens of the hepatitis b virus
EP3473639A4 (en) Hepatitis c virus inhibitor and application
ZA202104076B (en) Hepatitis b virus vaccine and uses thereof
GB201702193D0 (en) Hepatitis E virus vaccine
EP3445367A4 (en) Hepatitis c virus inhibitors
PL3244921T3 (en) An immunogenic vaccine against the hcv and/or hbv